Filing Details
- Accession Number:
- 0001179110-14-012583
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-08 10:09:25
- Reporting Period:
- 2014-08-06
- Filing Date:
- 2014-08-08
- Accepted Time:
- 2014-08-08 10:09:25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1586105 | Egalet Corp | EGLT | Pharmaceutical Preparations (2834) | 463575334 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1591231 | Stan Musial | 460 East Swedesford Road Suite 1050 Wayne PA 19087 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2014-08-06 | 7,648 | $11.06 | 131,552 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-08-07 | 6,272 | $11.03 | 125,820 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on February 11, 2014.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.80 to $11.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.70 to $11.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.